Edoxaban chemical structure
Chemical structureResearch use only
CAT. NO. DC8305Featured

Edoxaban

Pack Sizes & Prices

TotalUS$450
We match the best price and quality on market.
Product overview

Description & Application

Edoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention in patients with atrial fibrillation, an elderly population that frequently receives aspirin (ASA) and/or nonsteroidal anti-inflammatory drugs for concurrent illnesses. in vitro: Edoxaban PK was not affected by concomitant low-dose ASA or naproxen, but high-dose ASA increased systemic exposure of edoxaban by approximately 30%. The effects of edoxaban on prothrombin time, activated partial thromboplastin time, international normalized ratio, anti-FXa, and intrinsic FXa activity were not influenced by administration with ASA or naproxen. Inhibition of platelet aggregation by high-dose ASA, low-dose ASA, or naproxen was not affected by edoxaban. in vivo: Forty-eight subjects, aged 18 to 45 years, received either edoxaban 60 mg once daily × 7 days (n = 24) or digoxin 0.25 mg twice daily × 2 days and once daily × 5 days (n = 24) and then concomitantly for 7 days. Serial blood and urine samples were collected for digoxin and edoxaban concentrations on days 7 and 14. Serial coagulation assays were measured for edoxaban on days 7 and 14. Edoxaban PK parameters demonstrated mild increases in area under the curve and peak concentrations of 9.5% and 15.6%, respectively. For the detailed information of Edoxaban, the solubility of Edoxaban in water, the solubility of Edoxaban in DMSO, the solubility of Edoxaban in PBS buffer, the animal experiment (test) of Edoxaban, the cell expriment (test) of Edoxaban, the in vivo, in vitro and clinical trial test of Edoxaban, the EC50, IC50,and affinity,of Edoxaban, For the detailed information of Edoxaban, the solubility of Edoxaban in water, the solubility of Edoxaban in DMSO, the solubility of Edoxaban in PBS buffer, the animal experiment (test) of Edoxaban, the cell expriment (test) of Edoxaban, the in vivo, in vitro and clinical trial test of Edoxaban, the EC50, IC50,and affinity,of Edoxaban, Please contact DC Chemicals.

ParameterValue
Chemical NameEdoxaban TsOH salt
CAS No.480449-71-6
SynonymsEdoxaban TsOH salt;[14C]-Edoxaban tosylate;DU-176b;Edoxaban (tosylate);Edoxaban (TsOH salt);edoxaban tosilate;Edoxaban tosylate
FormulaC24H30N7O4Scl.C7H8O3S
M.Wt720.259120000001
SMILESO=C(N(C)C)[C@@H](CC1)C[C@H]([C@H]1NC(C(NC(C=C2)=NC=C2Cl)=O)=O)NC(C3=NC(CC4)=C(CN4C)S3)=O.O=S(C5=CC=C(C)C=C5)(O)=O
Purity>98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

Edoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention in patients with atrial fibrillation, an elderly population that frequently receives aspirin (ASA) and/or nonsteroidal anti-inflammatory drugs for concurrent illnesses. in vitro: Edoxaban PK was not affected by concomitant low-dose ASA or naproxen, but high-dose ASA increased systemic exposure of edoxaban by approximately 30%. The effects of edoxaban on prothrombin time, activated partial thromboplastin time, international normalized ratio, anti-FXa, and intrinsic FXa activity were not influenced by administration with ASA or naproxen. Inhibition of platelet aggregation by high-dose ASA, low-dose ASA, or naproxen was not affected by edoxaban. in vivo: Forty-eight subjects, aged 18 to 45 years, received either edoxaban 60 mg once daily × 7 days (n = 24) or digoxin 0.25 mg twice daily × 2 days and once daily × 5 days (n = 24) and then concomitantly for 7 days. Serial blood and urine samples were collected for digoxin and edoxaban concentrations on days 7 and 14. Serial coagulation assays were measured for edoxaban on days 7 and 14. Edoxaban PK parameters demonstrated mild increases in area under the curve and peak concentrations of 9.5% and 15.6%, respectively. For the detailed information of Edoxaban, the solubility of Edoxaban in water, the solubility of Edoxaban in DMSO, the solubility of Edoxaban in PBS buffer, the animal experiment (test) of Edoxaban, the cell expriment (test) of Edoxaban, the in vivo, in vitro and clinical trial test of Edoxaban, the EC50, IC50,and affinity,of Edoxaban, For the detailed information of Edoxaban, the solubility of Edoxaban in water, the solubility of Edoxaban in DMSO, the solubility of Edoxaban in PBS buffer, the animal experiment (test) of Edoxaban, the cell expriment (test) of Edoxaban, the in vivo, in vitro and clinical trial test of Edoxaban, the EC50, IC50,and affinity,of Edoxaban, Please contact DC Chemicals.

In Vitro

No in vitro data are provided in the current product source. Contact us for further information.

In Vivo

No in vivo data are provided in the current product source. Contact us for further information.

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Product documentation

Refer to the certificate supplied with your lot for batch-specific release results.

Handling guide

2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Solution calculator

Related research products

PF-06282999 chemical structureDC10500

PF-06282999

PF-06282999 is a potent and selective myeloperoxidase inhibitor which is potential useful for the treatment of cardiovascular diseases.

View activity & prices
Cangrelor free acid chemical structureDC7005

Cangrelor free acid

Cangrelor is a P2Y12 inhibitor, and was approved in June 2015 as an antiplatelet drug for intravenous application. Cangrelor is a high-affinity, reversible inhibitor of P2Y12 receptors that causes almost complete…

View activity & prices

Cart

Request quotation